1,2-Dichloroethane → N-(4-((2R)-4-(4-(2-(tert-butyldiphenylsilyloxy)-3-fluoropropyl)piperazin-1-yl)-1-(phenylthio)butan-2-ylamino)-3-(trifluoromethylsulfonyl)phenyl sulfonyl)-4-(4-((R)-(4'-chlorobiphenyl-2-yl)(hydroxy)methyl)piperidin-1-yl)benzamide
반응식
[Cl:1][C:2]1[CH:7]=[CH:6][C:5]([C:8]2[CH:13]=[CH:12][CH:11]=[CH:10][C:9]=2[C@H:14]([OH:30])[CH:15]2[CH2:20][CH2:19][N:18]([C:21]3[CH:29]=[CH:28][C:24]([C:25](O)=[O:26])=[CH:23][CH:22]=3)[CH2:17][CH2:16]2)=[CH:4][CH:3]=1.[Si:31]([O:48][C@@H:49]([CH2:86][F:87])[CH2:50][N:51]1[CH2:56][CH2:55][N:54]([CH2:57][CH2:58][C@@H:59]([NH:68][C:69]2[CH:74]=[CH:73][C:72]([S:75]([NH2:78])(=[O:77])=[O:76])=[CH:71][C:70]=2[S:79]([C:82]([F:85])([F:84])[F:83])(=[O:81])=[O:80])[CH2:60][S:61][C:62]2[CH:67]=[CH:66][CH:65]=[CH:64][CH:63]=2)[CH2:53][CH2:52]1)([C:44]([CH3:47])([CH3:46])[CH3:45])([C:38]1[CH:43]=[CH:42][CH:41]=[CH:40][CH:39]=1)[C:32]1[CH:37]=[CH:36][CH:35]=[CH:34][CH:33]=1.[Si](O[C@H](CF)CN1CCN(CC[C@@H](NC2C=CC(S(N)(=O)=O)=CC=2S(C(F)(F)F)(=O)=O)CSC2C=CC=CC=2)CC1)(C(C)(C)C)(C1C=CC=CC=1)C1C=CC=CC=1.C(Cl)CCl>CN(C1C=CN=CC=1)C>[Si:31]([O:48][CH:49]([CH2:86][F:87])[CH2:50][N:51]1[CH2:56][CH2:55][N:54]([CH2:57][CH2:58][C@@H:59]([NH:68][C:69]2[CH:74]=[CH:73][C:72]([S:75]([NH:78][C:25](=[O:26])[C:24]3[CH:28]=[CH:29][C:21]([N:18]4[CH2:19][CH2:20][CH:15]([C@H:14]([C:9]5[CH:10]=[CH:11][CH:12]=[CH:13][C:8]=5[C:5]5[CH:4]=[CH:3][C:2]([Cl:1])=[CH:7][CH:6]=5)[OH:30])[CH2:16][CH2:17]4)=[CH:22][CH:23]=3)(=[O:77])=[O:76])=[CH:71][C:70]=2[S:79]([C:82]([F:84])([F:83])[F:85])(=[O:80])=[O:81])[CH2:60][S:61][C:62]2[CH:67]=[CH:66][CH:65]=[CH:64][CH:63]=2)[CH2:53][CH2:52]1)([C:44]([CH3:45])([CH3:46])[CH3:47])([C:38]1[CH:39]=[CH:40][CH:41]=[CH:42][CH:43]=1)[C:32]1[CH:37]=[CH:36][CH:35]=[CH:34][CH:33]=1참가 물질
반응물 4
생성물 1
시약·촉매·용매 1
실험 절차
(R)-4-(4-((4′-chlorobiphenyl-2-yl)(hydroxy)methyl)piperidin-1-yl)benzoic acid (INTERMEDIATE 40, 58 mg, 0.14 mmol), 4-((R)-4-(4-((R)-2-(tert-butyldiphenylsilyloxy)-3-fluoropropyl)piperazin-1-yl)-1-(phenylthio)butan-2-ylamino)-3-(trifluoromethylsulfonyl)benzenesulfonamide and 4-((R)-4-(4-((S)-2-(tert-butyldiphenylsilyloxy)-3-fluoropropyl)piperazin-1-yl)-1-(phenylthio)butan-2-ylamino)-3-(trifluoromethylsulfonyl)benzenesulfonamide mixture of diastereomers (INTERMEDIATE 39, 120 mg, 0.14 mmol), DMAP (34 mg, 0.28 mmol), and EDC (53 mg, 0.28 mmol) were placed in a 40 ml vial and flushed with nitrogen. DCM (2.8 ml) was added, and the solution was stirred at room temperature overnight. The reaction mixture was diluted with DCM and washed with 1N aq. sodium bisulfate followed by a saturated aq. sodium bicarbonate. The organic layer was dried (Na2SO4), filtered, and evaporated under reduced pressure to give N-(4-((2R)-4-(4-(2-(tert-butyldiphenylsilyloxy)-3-fluoropropyl)piperazin-1-yl)-1-(phenylthio)butan-2-ylamino)-3-(trifluoromethylsulfonyl)phenylsulfonyl)-4-(4-((R)-(4′-chlorobiphenyl-2-yl)(hydroxy)methyl)piperidin-1-yl)benzamide (EXAMPLE 6, STEP 1, 180 mg), which was used in the preparation of EXAMPLE 6, STEP 2, without further purification.
후처리
- customflushed with nitrogen
- additionDCM (2.8 ml) was added
- additionThe reaction mixture was diluted with DCM
- washwashed with 1N aq. sodium bisulfate
- dry with materialThe organic layer was dried (Na2SO4)
- filtrationfiltered
- customevaporated under reduced pressure
출처 및 근거
- ORD 기록
- ord-41ef8ac94f904f878263da9e36151a67
- 출처 데이터셋
- uspto-grants-2016_02
- 특허 번호
- US09248140B2
반응 노트
불러오는 중…